The increasing incidence of cerebrovascular and cognitive disorders in Uzbekistan, driven by a growing information load and an aging population, has led to a heightened demand for effective nootropic medications. The pharmaceutical market is adapting to this demand through a diversified range of drugs, including both imported and domestically produced products. Aim. This study aims to evaluate the dynamics of the nootropic drug market in the Republic of Uzbekistan from 2015 to 2024 in both physical and monetary terms, including the analysis of import volumes, domestic production, key market players, dosage forms, and trends in international nonproprietary names. Materials and methods. The study utilized aggregated data on the registration, import, and production of nootropic drugs classified under ATC group N06BX. Marketing analysis methods and qualimetric tools were applied to identify quantitative trends, structural shifts over the study period. Results and discussion. The article presents an analysis of the dynamics of the nootropic drug market in the Republic of Uzbekistan over the period 2015–2024. It examines quantitative changes in both physical and monetary terms, as well as the structure of imports and domestic production. Key trends are identified, including an increase in nootropic consumption up to 2022 followed by a subsequent decline, the strengthening of domestic manufacturers' positions, and changes in the assortment and consumption structure by international nonproprietary names. A comparative analysis of supplies from CIS and non-CIS countries is provided, along with an evaluation of the activity of leading domestic companies. Particular attention is given to dosage forms. The findings of the study may be used to assess the current state of the pharmaceutical market and to inform strategic planning for the development of the nootropic drug sector in Uzbekistan. Conclusions The nootropic drug market in Uzbekistan shows cyclical dynamics with strong domestic development potential. Market fluctuations reflect clinical guideline revisions and increased emphasis on evidence-based prescribing. The study highlights the growing role of local manufacturers and the shift toward more complex and effective nootropic formulations.
Saydalieva et al. (Tue,) studied this question.